Portal de investigação
Lessons from Four Decades of Systemic Amyloidosis with Renal Involvement
Autores da FMUP
Participantes de fora da FMUP
- Oliveira-Silva, C
- Marques, N
- Pinho, A
- Poinhos, R
- Nunes, AT
- Rodrigues-Pereira, P
- Silva, R
- Praca, A
- Frazao, J
Unidades de investigação
Abstract
Background: Apart from ATTR amyloidosis, the epidemiology and outcomes of the most common subtypes of systemic amyloidosis in Portugal remain primarily unknown. Methods: This retrospective cohort study evaluated patients with renal biopsy-proven amyloidosis, diagnosed from January 1978 to December 2019. Follow-up started at kidney disease presentation and ended at death or August 2020. Clinical presentation, survival, and prognostic factors were analysed. Results: Of 123 patients with amyloid nephropathy, 111 had definite amyloid typing and were analysed. AA amyloidosis was the most frequent type (56.1%) and was related mainly to chronic infection (47.8%) and chronic inflammatory arthritis (29.0%). AL amyloidosis was present in 25.2% of patients and hereditary forms in 6.5% (4.1% AFibE526V, 2.4% ATTRV30M). During follow-up, 73.9% of AA and 54.8% of AL patients progressed to end-stage renal disease, and 79.7% of AA and 77.4% of AL died; median overall survival was 66.0 (95% CI, 33.0-99.0) and 18.0 (95% CI, 9.3-26.7) months (p = 0.025), respectively. There were no significant differences in renal outcome and survival on dialysis between these two types. In multivariate analysis, cardiac involvement at presentation (HR 6.26 [95% CI, 2.89-13.56]) and estimated glomerular filtration rate <30 mL/min/1.73 m(2) (HR 2.05 [95% CI, 1.06-3.99]) independently influenced AA and AL amyloidosis survival. Cardiac involvement at presentation was an independent predictor of death (HR 9.65 [95% CI, 2.91-31.95]) and early mortality in AL amyloidosis. Conclusions: In Portugal, AA amyloidosis and related chronic infections are still relevant. Regarding AL amyloidosis, the low incidence and advanced disease at presentation result from missed and erroneous diagnoses, leading to delayed referrals and poor outcomes in these patients.
© 2022 S. Karger AG, Basel.
Dados da publicação
- ISSN/ISSNe:
- 1660-8151, 1660-2129
- Tipo:
- Article
- Páginas:
- 158-169
- DOI:
- 10.1159/000525675
- Link para outro recurso:
- www.scopus.com
NEPHRON S. Karger AG
Citações Recebidas na Scopus: 1
Documentos
- Não há documentos
Filiações
Keywords
- Amyloidosis; Cardiac amyloidosis; Hemodialysis; Kidney biopsy; Survival
Proyectos asociados
Rituximab na terapêutica da nefropatia membranosa
Investigador Principal: Manuel Jesus Falcão Pestana Vasconcelos
Estudo Clínico Académico (Rituximab) . 2020
Risk evaluation of metformin use in patients with kidney injury.
Investigador Principal: Susana Maria Moreira Sampaio Norton
Estudo Clínico Académico (Metformin) . 2020
Lessons from four decades of systemic amyloidosis with renal involvement
Investigador Principal: Isabel Cristina Pinho Tavares Salomé
Estudo Clínico Académico . 2021
COVID-19 em Doentes em Hemodiálise: uma tempestade moderada?
Investigador Principal: Isabel Cristina Pinho Tavares Salomé
Estudo Clínico Académico . 2021
Citar a publicação
Oliveira C,Marques N,Pinho A,Poinhos R,Bergantim R,Nunes AT,Sampaio S,Rodrigues P,Silva R,Praca A,Frazao J,Pestana M,Tavares I. Lessons from Four Decades of Systemic Amyloidosis with Renal Involvement. Nephron. 2023. 147. (3-4):p. 158-169. IF:2,500. (3).
